Literature DB >> 11007365

Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity.

N P Restifo1.   

Abstract

The immunological consequences of apoptosis have been hotly debated. Apoptosis was originally described as a set of cellular morphological changes that occur in the absence of inflammation but the term has been redefined on the basis of a set of conserved molecular events that include the activation of caspases. Though the apoptosis occurring during normal development is immunologically bland or even tolerizing, the apoptotic death after viral infection or after the ligation of Fas can trigger powerful innate and adaptive immune responses. The molecular machinery at the nexus of apoptosis and inflammation includes caspase-1 --an activator of IL-1beta and IL-18 - as well as the double-stranded-RNA-dependent protein kinase pathway and RNaseL pathway, which are key effectors of antiviral immunity. New proapoptotic vaccines induce immune responses that may be able to prevent or treat infectious disease and cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11007365      PMCID: PMC1955758          DOI: 10.1016/s0952-7915(00)00148-5

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  79 in total

1.  Fas counter-attack--the best form of tumor defense?

Authors:  J O'Connell; M W Bennett; G C O'Sullivan; J K Collins; F Shanahan
Journal:  Nat Med       Date:  1999-03       Impact factor: 53.440

Review 2.  The human 2',5'-oligoadenylate synthetase family: interferon-induced proteins with unique enzymatic properties.

Authors:  D Rebouillat; A G Hovanessian
Journal:  J Interferon Cytokine Res       Date:  1999-04       Impact factor: 2.607

Review 3.  The central effectors of cell death in the immune system.

Authors:  J C Rathmell; C B Thompson
Journal:  Annu Rev Immunol       Date:  1999       Impact factor: 28.527

4.  Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation.

Authors:  V Bronte; D B Chappell; E Apolloni; A Cabrelle; M Wang; P Hwu; N P Restifo
Journal:  J Immunol       Date:  1999-05-15       Impact factor: 5.422

5.  Cancer therapy using a self-replicating RNA vaccine.

Authors:  H Ying; T Z Zaks; R F Wang; K R Irvine; U S Kammula; F M Marincola; W W Leitner; N P Restifo
Journal:  Nat Med       Date:  1999-07       Impact factor: 53.440

6.  The role of 2'-5' oligoadenylate-activated ribonuclease L in apoptosis.

Authors:  J C Castelli; B A Hassel; A Maran; J Paranjape; J A Hewitt; X L Li; Y T Hsu; R H Silverman; R J Youle
Journal:  Cell Death Differ       Date:  1998-04       Impact factor: 15.828

7.  Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition.

Authors:  T Z Zaks; D B Chappell; S A Rosenberg; N P Restifo
Journal:  J Immunol       Date:  1999-03-15       Impact factor: 5.422

8.  Recombinant virus vaccination against "self" antigens using anchor-fixed immunogens.

Authors:  K R Irvine; M R Parkhurst; E P Shulman; J P Tupesis; M Custer; C E Touloukian; P F Robbins; A G Yafal; P Greenhalgh; R P Sutmuller; R Offringa; S A Rosenberg; N P Restifo
Journal:  Cancer Res       Date:  1999-06-01       Impact factor: 12.701

9.  Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.

Authors:  A van Elsas; A A Hurwitz; J P Allison
Journal:  J Exp Med       Date:  1999-08-02       Impact factor: 14.307

Review 10.  Cytokines as endogenous pyrogens.

Authors:  C A Dinarello
Journal:  J Infect Dis       Date:  1999-03       Impact factor: 5.226

View more
  41 in total

1.  Countering the 'counterattack' hypothesis.

Authors:  N P Restifo
Journal:  Nat Med       Date:  2001-03       Impact factor: 53.440

Review 2.  Hierarchy, tolerance, and dominance in the antitumor T-cell response.

Authors:  N P Restifo
Journal:  J Immunother       Date:  2001 May-Jun       Impact factor: 4.456

3.  Vaccines to die for.

Authors:  N P Restifo
Journal:  Nat Biotechnol       Date:  2001-06       Impact factor: 54.908

4.  Molecular basis of neurovirulence of flury rabies virus vaccine strains: importance of the polymerase and the glycoprotein R333Q mutation.

Authors:  Lihong Tao; Jinying Ge; Xijun Wang; Hongyue Zhai; Tao Hua; Bolin Zhao; Dongni Kong; Chinglai Yang; Hualan Chen; Zhigao Bu
Journal:  J Virol       Date:  2010-06-10       Impact factor: 5.103

Review 5.  Cellular immunotherapy for soft tissue sarcomas.

Authors:  Steven Eric Finkelstein; Mayer Fishman; Anthony P Conley; Dmitry Gabrilovich; Scott Antonia; Alberto Chiappori
Journal:  Immunotherapy       Date:  2012-03       Impact factor: 4.196

Review 6.  Cancer vaccines: progress reveals new complexities.

Authors:  Zhiya Yu; Nicholas P Restifo
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

7.  DNA vaccines and apoptosis: to kill or not to kill?

Authors:  Wolfgang W Leitner; Nicholas P Restifo
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

8.  Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines.

Authors:  Wolfgang W Leitner; Leroy N Hwang; Elke S Bergmann-Leitner; Steven E Finkelstein; Stephan Frank; Nicholas P Restifo
Journal:  Vaccine       Date:  2004-03-29       Impact factor: 3.641

Review 9.  Dendritic cell vaccines in cancer immunotherapy: from biology to translational medicine.

Authors:  Hongmei Xu; Xuetao Cao
Journal:  Front Med       Date:  2011-12       Impact factor: 4.592

10.  Glycoprotein of nonpathogenic rabies viruses is a key determinant of human cell apoptosis.

Authors:  Christophe Préhaud; Stéphanie Lay; Bernhard Dietzschold; Monique Lafon
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.